Summary
We studied metabolic progression to IDDM in a cohort of adults who are ICA-positive and have associated autoimmune endocrine disease or circulating organ-specific autoantibodies (the Polyendocrine Study). Of the 186 individuals recruited 27 developed overt diabetes after a median follow-up of 4.5 years (range 0.4–12). Of these, eight patients did not require insulin treatment until at least 6 months after clinical diagnosis, with an interval of 1.8 years (1.2–5.7). An IVGTT was performed in 38 subjects and 23 had sequential studies. Of the initial 38 subjects six developed diabetes and only three showed a loss of FPIR to glucose (below the first percentile of a normal control group) before clinical onset of the disease. An additional three subjects showed a loss of the FPIR, and all still have normal glucose tolerance after median follow-up of 28 months (22–95). A “whole” or “mixed” pattern of islet cell staining was found in five of the six patients who developed diabetes and antibodies against an islet 37 k-antigen were detectable in four patients, all of whom required insulin soon after diagnosis. A beta-cell “selective” ICA staining pattern was seen in 14 of 17 subjects who did not develop diabetes and the “mixed” pattern in only three. None of this group had detectable 37k-antibodies. We conclude that metabolic deterioration is slow in polyendocrine patients, and that the IVGTT has less prognostic significance in this group than in first degree relatives of patients with IDDM. In contrast, the presence of the “whole” or “mixed” ICA staining pattern or of 37k-antibodies can identify a high risk of progression to IDDM within this polyendocrine population and may indicate the rate of metabolic deterioration.
Article PDF
Similar content being viewed by others
Abbreviations
- IDDM:
-
Insulin-dependent diabetes mellitus
- ICA:
-
islet cell antibodies
- IVGTT:
-
intravenous glucose tolerance test
- FPIR:
-
first phase insulin response
- OGTT:
-
oral glucose tolerance test
- GAD:
-
glutamic acid decarboxylase
- JDF:
-
Juvenile Diabetes Foundation
References
Tarn AC, Thomas JM, Dean BM et al. (1988) Predicting insulin-dependent diabetes. Lancet 1: 845–850
Ziegler AG, Ziegler R, Vardi P, Jackson R, Soeldner S, Eisenbarth G (1989) Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with Type 1 diabetes. Diabetes 38: 1320–1325
Atkinson MA, Maclaren NK, Scharp DW, Lacy PE, Riley WJ (1990) 64,000 Mr autoantibodies as predictors of insulin-dependent diabetes. Lancet 335: 1357–1360
Baskkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, Lernmark Å (1982) Antibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 298: 167–169
Srikanta S, Ganda OP, Eisenbarth GS, Soeldner JS (1983) Islet cell antibodies and beta-cell function in monozygotic triplets and twins initially discordant for type 1 diabetes mellitus. N Engl J Med 308: 322–325
Bleich D, Jackson RA, Soeldner JS, Eisenbarth GS (1990) Analysis of metabolic progression to type 1 diabetes in ICA + relatives of patients with type 1 diabetes. Diabetes Care 13: 111–118
Jackson RA, Soeldner JS, Eisenbarth GS (1989) Testing the dual parameter model for predicting time to diabetes. Clin Res 37: 57 (Abstract)
Bosi E, Becker F, Bonifacio E et al. (1991) Progression to type 1 diabetes in autoimmune endocrine patients with islet cell antibodies. Diabetes 40: 977–984
Genovese S, Bonifacio E, McNally JM et al. (1992) Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35: 385–388
Christie MR, Vohra G, Champagne P, Daneman D, Delovitch TL (1990) Distinct antibody specificities of a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J Exp Med 172: 789–795
Christie MR, Hollands JA, Brwon TS, Michelsen BK, Delovitch TL (1993) Detection of pancreatic islet 64,000 Mr autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 92: 240–248
Genovese S, Cassidy D, Bonifacio E, Bottazzo GF, Christie MR (1991) Antibodies to 37/40kD tryptic fragments of 64 kD antigen are markers of rapid progression to type 1 insulin-dependent diabetes. Diabetes Res Clin Pract 14 [Suppl 1]: S11 (Abstract)
Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiency. Lancet II: 1279–1282
Bonifacio E, Lernmark Å, Dawkins RL (1988) Serum exchange and use of dilution have improved precision of measurement of islet cell antibodies. J Immunol Methods 106: 83–88
Christie MR, Brown TJ, Cassidy D (1992) Binding of antibodies in sera from type 1 (insulin-dependent) diabetic patients to glutamate decarboxylase from rat tissues. Evidence for antigenic and non-antigenic forms of the enzyme. Diabetologia 35: 380–384
Scherbaum WA, Mirakian R, Pujol-Borrell R, Dean BM, Bottazzo GF (1986) Immunocytochemistry in the study and diagnosis of organ-specific autoimmune diseases. In: Polak JM, Van Noorden S (eds) Immunocytochemistry — Modern methods and applications, 2nd edn. Wright, Bristol, pp 456–476
Vardi P, Crisa L, Jackson RA et al. (1991) Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 34: 93–102
Bingley PJ, Colman PG, Eisenbarth GS et al. (1992) Standardization of IVGTT to predict IDDM. Diabetes Care 10: 1313–1316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, R., Genovese, S., Bosi, E. et al. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia 37, 365–371 (1994). https://doi.org/10.1007/BF00408472
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00408472